The growing landscape of the India pharmaceuticals is witnessing significant interest on Retatrutide, a novel dual GIP and GLP-1 receptor exhibiting potential for metabolic disorders. This protein is generating considerable anticipation within the healthcare community, particularly as local companies pursue commercialization deals. The prevailing s